Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Condition: Pancreatic Cancer Interventions: Drug: Atezolizumab; Biological: RO7198457; Drug: mFOLFIRINOX Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Pancreas | Pancreatic Cancer | Research | Study | Vaccines